114 related articles for article (PubMed ID: 33024759)
1. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy
Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
World J Clin Cases; 2020 Sep; 8(18):4022-4033. PubMed ID: 33024759
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting.
Cartwright TH; Parisi M; Espirito JL; Wilson TW; Pelletier C; Patel M; Babiker HM
Drugs Real World Outcomes; 2018 Sep; 5(3):149-159. PubMed ID: 29946913
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer.
Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
World J Clin Cases; 2020 Sep; 8(17):3718-3729. PubMed ID: 32953848
[TBL] [Abstract][Full Text] [Related]
4. FOLFIRINOX
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; An C; Park MS; Bang S
World J Gastrointest Oncol; 2020 Feb; 12(2):182-194. PubMed ID: 32104549
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Fukahori M; Okabe Y; Shimokawa M; Otsuka T; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Makiyama A; Taguchi H; Honda T; Ushijima T; Miwa K; Shibuki T; Nio K; Ide Y; Ureshino N; Mizuta T; Mitsugi K; Shirakawa T
Sci Rep; 2023 Nov; 13(1):19399. PubMed ID: 37938630
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.
Martín AJ; Alfonso PG; Rupérez AB; Jiménez MM
Oncol Lett; 2016 Jul; 12(1):727-730. PubMed ID: 27347207
[TBL] [Abstract][Full Text] [Related]
8. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.
de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
J Gastrointest Oncol; 2018 Oct; 9(5):806-819. PubMed ID: 30505579
[TBL] [Abstract][Full Text] [Related]
10. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
[TBL] [Abstract][Full Text] [Related]
11.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
12. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
13. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
14. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
17. A Near-Complete Response to Treatment with Gemcitabine plus nab (®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report.
Shakir AR
Case Rep Oncol; 2014 Sep; 7(3):711-7. PubMed ID: 25493084
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
Zhang Y; Hochster H; Stein S; Lacy J
Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
[TBL] [Abstract][Full Text] [Related]
19. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Sohal DP; Mangu PB; Khorana AA; Shah MA; Philip PA; O'Reilly EM; Uronis HE; Ramanathan RK; Crane CH; Engebretson A; Ruggiero JT; Copur MS; Lau M; Urba S; Laheru D
J Clin Oncol; 2016 Aug; 34(23):2784-96. PubMed ID: 27247222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
